ASH 2017 | Clinical translation of carfilzomib trial data for MM treatment
The proteasome inhibitor carfilzomib has been investigated for the treatment of relapsed/refractory multiple myeloma (MM) in two Phase III clinical trials, ASPIRE (NCT01080391) and ENDEAVOUR (NCT01080391), with promising results. In this interview, Greg Friberg, MD, of Amgen Inc., Thousand Oaks, CA, discuses subanalyses of the robustness of the study data. Dr Friberg highlights how this data will help clinicians to determine the best treatment combinations for their patients. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up